Dominantly inherited apathy, central hypoventilation, and parkinson’s syndrome: Clinical, biochemical, and neuropathologic studies of 2 new cases

Neurology

Volumn 40, Issue 12, 1990, Pages 1882-1887

  Perry, T L ^a,a   Wright, J M ^a   Berry, K ^a   Hansen, S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 5 HYDROXYINDOLEACETIC ACID; AMITRIPTYLINE; FLUOXETINE; HOMOVANILLIC ACID; ISONIAZID;

ADULT; APATHY; ARTICLE; AUTOPSY; CASE REPORT; ETIOLOGY; FRONTAL CORTEX; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOVENTILATION; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; THALAMUS;

ADULT; AMINO ACIDS; BRAIN; CASE REPORT; DEPRESSION; DOPAMINE; FEMALE; GENES, DOMINANT; HUMAN; MALE; MIDDLE AGE; PARKINSON DISEASE; REFERENCE VALUES; SEROTONIN; SLEEP APNEA SYNDROMES; SUPPORT, NON-U.S. GOV'T;

EID: 0025607841     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.40.12.1882     Document Type: Article

References (22)

1. Perry TL, Bratty PJA, Hansen S, Kennedy J, Urquhart N, Dolman CL. Hereditary mental depression and parkinsonism with taurine deficiency. Arch Neurol 1975;32:108-113.
2. Purdy A, Hahn A, Barnett MJM, et al. Familial fatal parkinsonism with alveolar hypoventilation and mental depression. Ann Neurol 1979;6:523-581.
3. Roy EP HI, Riggs JE, Martin JD, Ringel RA, Gutmann L. Familial parkinsonism, apathy, weight loss, and central hypoventilation: successful long-term management. Neurology 1988;38:637-639.
4. Perry TL. Hereditary mental depression with taurine deficiency: further studies, including a therapeutic trial of taurine administration. In: Huxtable R, Barbeau A, eds. Taurine. New York: Raven Press, 1976:365-374.
5. Perry TL, Hansen S, Kennedy J. CSF amino acids and plasma- CSF amino acid ratios in adults. J Neurochem 1975;24:587-589.
6. Perry TL, Hansen S, Wall RA, Gauthier SG. Human CSF GABA concentrations: revised downward for controls, but not decreased in Huntington’s chorea. J Neurochem 1982;28:766-773.
7. Perry TL, Yong VW, Ito M, et al. l-Methyl-4-phenyl-l,2,3,6- tetrahydropyridine (MPTP) does not destroy nigrostriatal neurons in the scorbutic guinea pig. Life Sci 1985;36:1233-1238.
8. Perry TL, Hansen S, Gandham SS. Postmortem changes of amino compounds in human and rat brain. J Neurochem 1981;36:406-412.
9. Guan X-M, McBride WJ. Fluoxetine increases extracellular levels of serotonin in the nucleus accumbens. Brain Res Bull 1988;21:43-46.
10. Bertilsson L. 5-Hydroxyindoleacetic acid in cerebrospinal fluid: methodological and clinical aspects. Life Sci 1987;41:821-824.
11. Perry TL, Kish SJ, Hansen S, et al. Elevation of brain GABA content by chronic low-dosage administration of hydrazine, a metabolite of isoniazid. J Neurochem 1981;37:32-39.
12. Perry TL, Wall RA, Hansen S. Brain amino compounds in a Huntington’s disease patient on isoniazid therapy. Neurology 1985;35:755-758.
13. Gilbert JJ, Kish SJ, Chang L-J, Morito C, Shannak K, Hor- nykiewicz O. Dementia, parkinsonism and motor neuron disease: neurochemical and neuropathological correlates. Ann Neurol 1988;24:688-691.
14. Perry TL, Norman MG, Yong VW, et al. Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. Ann Neurol 1985;18:482-484.
15. Lloyd KG, Davidson L, Homykiewicz O. The neurochemistry of Parkinson’s disease: effect of L-dopa therapy. J Pharmacol Exp Ther 1975;195:453-464.
16. Davidson DLW, Yates CM, Mawdsley C, Pullar I, Wilson H. CSF studies on the relationship between dopamine and 5-hydroxytryp- tamine in parkinsonism and other movement disorders. J Neurol Neurosurg Psychiatry 1977;40:1136-1141.
17. Gibson CJ, Logue M, Growdon JH. CSF monoamine metabolite levels in Alzheimer’s and Parkinson’s disease. Arch Neurol 1985;42:489-492.
18. Kurlan R, Goldblatt D, Zaczek R, et al. Cerebrospinal fluid homo- vanillic acid and parkinsonism in Huntington’s disease. Ann Neurol 1988;24:282-284.
19. Bostwick JR, Landers DW, Crawford G, Lau K, Appel SH. Purification and characterization of a central cholinergic enhancing factor from rat brain: its identity as phosphoethanolamine. J Neurochem 1989;53:448-458.
20. Ellison DW, Beal MR, Martin JB. Phosphoethanolamine and ethanolamine are decreased in Alzheimer’s disease and Huntington’s disease. Brain Res 1987;417:389-392.
21. Perry TL, Yong VW, Bergeron C, Hansen S, Jones K. Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer’s disease. Ann Neurol 1987;21:331-336.
22. Rinne JO, Rummukainen J, Paljarvi L, Rinne UK. Dementia in Parkinson’s disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989;26:47-50.